-
公开(公告)号:NO992705D0
公开(公告)日:1999-06-03
申请号:NO992705
申请日:1999-06-03
Applicant: ABBOTT LAB
Inventor: HOLLADAY MARK W , ARNERIC STEPHEN P , BAI HAO , DART MICHAEL J , LIN NAN-HORNG , LYNCH JOHN K , OR YAT SUN , RYTHER KEITH B , SULLIVAN JAMES P , WASICAK JAMES T , EHRLICH PAUL P
IPC: A61P25/04 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/485 , A61P25/28 , A61P29/00 , C07D205/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D
Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.
-
公开(公告)号:CA2273917A1
公开(公告)日:1998-06-18
申请号:CA2273917
申请日:1997-12-10
Applicant: ABBOTT LAB
Inventor: EHRLICH PAUL P , HOLLADAY MARK W , LIN NAN-HORNG , BAI HAO , SULLIVAN JAMES P , WASICAK JAMES T , RYTHER KEITH B , ARNERIC STEPHEN P , DART MICHAEL J , LYNCH JOHN K , OR YAT SUN
IPC: A61P25/04 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/485 , A61P25/28 , A61P29/00 , C07D205/04 , C07D401/12 , C07D401/14 , C07D405/14 , A61K31/44
Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.
-
公开(公告)号:AU687017B2
公开(公告)日:1998-02-19
申请号:AU5355794
申请日:1993-10-08
Applicant: ABBOTT LAB
Inventor: ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , ELLIOTT RICHARD L , GARVEY DAVID S , LEBOLD SUZANNE A , WASICAK JAMES T
IPC: A61K31/427 , A61K31/439 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P25/00 , A61P25/28 , C07D401/12 , C07D403/12 , C07D411/12 , C07D417/12 , C07D471/08 , C07D487/04 , A61K31/425 , A61K31/445 , A61K31/495 , A61K31/50 , A61K31/505
Abstract: Novel heterocyclic ether compounds of formula (I), wherein A, B and R are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are selective and potent ligands at cholinergic channel receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.
-
公开(公告)号:CA2136075A1
公开(公告)日:1994-04-28
申请号:CA2136075
申请日:1993-10-08
Applicant: ABBOTT LAB
Inventor: ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , ELLIOTT RICHARD L , GARVEY DAVID S , LEBOLD SUZANNE A , WASICAK JAMES T
IPC: A61K31/427 , A61K31/439 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P25/00 , A61P25/28 , C07D401/12 , C07D403/12 , C07D411/12 , C07D417/12 , C07D471/08 , C07D487/04 , C07D453/02 , A61K31/425 , A61K31/435 , A61K31/495
Abstract: 2136075 9408992 PCTABS00032 Novel heterocyclic ether compounds of formula (I), wherein A, B and R2 are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are selective and potent ligands at cholinergic channel receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.
-
公开(公告)号:CA2647592C
公开(公告)日:2014-01-28
申请号:CA2647592
申请日:2007-05-24
Applicant: ABBOTT LAB
Inventor: DIEBOLD ROBERT B , DJURIC STEVAN W , GIRANDA VINCENT L , HEXAMER LAURA , LIN NAN-HORNG , MIYASHIRO JULIE M , PENNING THOMAS D , PRZYTULINSKA MAGDALENA , SOWIN THOMAS , SULLIVAN GERARD , TAO ZHI-FU , TONG YUNSONG , VASUDEVAN ANIL , WANG LE , WOODS KEITH W , XIA ZHIREN , ZHANG HENRY Q
IPC: C07C225/20 , A61K31/132 , A61K31/505 , A61P35/00 , C07D249/14 , C07D277/64 , C07D285/06 , C07D333/20
Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, (see formula I) wherein X1, C1, and D1 are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting Plk1, Plk1 causes mitotic arrest, and inhibitors of Plk1 are cytotoxic agents that are useful for treatment of diseases of cellular proliferation, such as, for example, cancer.
-
96.
公开(公告)号:CA2223062C
公开(公告)日:2010-10-12
申请号:CA2223062
申请日:1996-05-28
Applicant: ABBOTT LAB
Inventor: HOLLADAY MARK W , LIN NAN-HORNG , RYTHER KEITH B , HE YUN
IPC: C07D401/12 , A61K31/00 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61P25/00 , A61P25/04 , C07D403/12 , C07D417/12
Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds having formula (I), wherein * is a chiral center and n, X, R1, R2, A andB are specifically defined, which are useful in controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions therof; and use of said compositions to selectively control synaptic transmission in mammals.
-
97.
公开(公告)号:SK286686B6
公开(公告)日:2009-03-05
申请号:SK8232003
申请日:2001-11-30
Applicant: ABBOTT LAB
Inventor: CLAIBORNE AKIYO K , GWALTNEY STEPHEN L II , HASVOLD LISA A , LI QUN , LI TOMGMEI , LIN NAN-HORNG , MANTEI ROBERT A , ROCKWAY TODD W , SHAM HING L , SULLIVAN GERARD M , TONG YUNSONG , WANG GARY T , WANG LE , WANG XILU , WANG WEIBO
IPC: C07D233/00 , A61K31/00 , A61K31/4164 , A61K31/4178 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61P35/00 , A61P43/00 , C07D233/54 , C07D233/64 , C07D277/20 , C07D277/30 , C07D401/00 , C07D401/12 , C07D405/12 , C07D409/12
Abstract: Disclosed are substituted imidazoles and thiazoles having formula (I) useful for inhibiting farnesyltransferase and also disclosed are farnesyltransferase-inhibiting compositions and the use these compounds in the production of medicaments for inhibiting farnesyltransferase.
-
98.
公开(公告)号:ES2286105T3
公开(公告)日:2007-12-01
申请号:ES01910414
申请日:2001-02-01
Applicant: ABBOTT LAB
Inventor: LIN NAN-HORNG , DONG LIMING
IPC: C07D213/65 , A61K31/44 , A61K31/444 , A61P25/00 , A61P25/04
Abstract: Un compuesto seleccionado del grupo que se compone de (a) un compuesto de la estructura o una sal del mismo farmacéuticamente admisible, en donde R1 es hidrógeno o metilo; R2 es hidrógeno; R5 es F, Cl o Br; y R6 es metilo, F, Cl o Br; (b) un compuesto de la estructura o una sal del mismo farmacéuticamente admisible, en donde R1 es hidrógeno o metilo; R2 es metilo; R5 es F, Cl o Br; y R6 es metilo, F, Cl o Br; (c) 5-[(S)-2-amino-1-propiloxi]-2-cloropiridina o una sal del mismo farmacéuticamente admisible; (d) ácido 5-[(R)-2-metilamino-1-propiloxi]-2-cloropiridina p-toluensulfónico; (e) 5-[(S)-2-amino-1-propiloxi]-2-fluoropiridina o una sal del mismo farmacéuticamente admisible; (f) ácido 5-[(R)-2-amino-1-propiloxi]-2-fluoropiridina p-toluensulfónico; (g) ácido 5-[(R)-2-metilamino-1-propiloxi]-2-fluoropiridina p-toluensulfónico; (h) ácido 5-[(R)-2-dimetilamino-1-propiloxi]-2-cloro-3-bromopiridina p-toluensulfónico; (i) ácido 5-[(S)-2-dimetilamino-1-propiloxi]-2-cloro-3-metilpiridina p-toluensulfónico; y (j) ácido 5-[(R)-2-dimetilamino-1-propiloxi]-2-cloro-3-metilpiridina p-toluensulfónico.
-
公开(公告)号:ES2261340T3
公开(公告)日:2006-11-16
申请号:ES01273519
申请日:2001-11-30
Applicant: ABBOTT LAB
Inventor: CLAIBORNE AKIYO K , GWALTNEY STEPHEN L II , HASVOLD LISA A , LI QUN , LI TOMGMEI , LIN NAN-HORNG
IPC: A61K31/4164 , A61K31/4178 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61P35/00 , A61P43/00 , C07D233/54 , C07D233/64 , C07D277/20 , C07D277/30 , C07D401/12 , C07D405/12 , C07D409/12
Abstract: Un compuesto de **fórmula** o una sal farmacéuticamente aceptable del mismo, donde E es un anillo carbocíclico, aromático o no aromático, de cinco, seis o siete miembros donde cero a tres átomos de carbono se reemplazan con nitrógeno; F y G se seleccionan independientemente entre el grupo constituido por C y N; con la condición de que cuando uno de F y G es N, el otro es C; cada uno de L1 y L2 se selecciona independientemente entre el grupo constituido por un enlace, alquenileno C2, alquinileno C2, O, NR9, C(O), S, S(O), SO2, SO2NR9, NR9SO2, C(O)NR9, NR9C(O) y CO2; X se selecciona entre el grupo constituido por S y NR7; R2 se selecciona entre el grupo constituido por hidrógeno, alcoxi, alquilo, amino, aminoalquilo, ciano, cianoalquilo, cicloalquilo, cicloalquilalquilo, halo, haloalquilo, heterociclo, (heterociclo)alquilo, hidroxi e hidroxialquilo; R3 se selecciona entre el grupo constituido por arilo, heterociclo y cicloalquilo; cada uno de R4-6 se selecciona independientemente entre el grupo constituido por hidrógeno, NR9C(O), C(O)NR9, alcanoílo, alquenilo, alcoxi, alcoxialquilo, alquilo, alquilsulfonilo, alquinilo, amido, amino, aminoalquilo, aminosulfonilo, arilo, arilalquilo, ariloxi, arilsulfonilo, azido, carboxi, ciano, cianoalquilo, cicloalquilo, cicloalquilalquilo, halo, haloalcoxi, haloalquilo, heterociclo, (heterociclo)alquilo, hidroxi, hidroxialquilo, nitro, nitroalquilo, oxo y tio(oxo); R7 se selecciona entre el grupo constituido por hidrógeno, alquilo, arilo, cicloalquilo, cicloalquilalquilo, heterociclo, (heterociclo) alquilo y trialquilsililo.
-
公开(公告)号:HU0600331A2
公开(公告)日:2006-10-28
申请号:HU0600331
申请日:2001-11-30
Applicant: ABBOTT LAB
Inventor: CLAIBORNE AKIYO K , GWALTNEY STEPHEN L II , HASVOLD LISA A , LI QUN , LI TOMGMEI , LIN NAN-HORNG , MANTEI ROBERT A , ROCKWAY TODD W , SHAM HING L VERNON HILLS , SULLIVAN GERARD M , TONG YUNSONG , WANG GARY T , WANG LE , WANG XILU , WANG WEIBO
IPC: C07D233/64 , A61K31/4164 , A61K31/4178 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61P35/00 , A61P43/00 , C07D233/54 , C07D277/20 , C07D277/30 , C07D401/12 , C07D405/12 , C07D409/12
Abstract: Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.
-
-
-
-
-
-
-
-
-